Arcus Capital Partners, LLC Galecto, Inc. Transaction History

Arcus Capital Partners, LLC

  • $255 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 27, 2023
BUY
$1.06 - $58.5 $513 - $28,314
484 New
484 $0

Others Institutions Holding GLTO

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $131M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Arcus Capital Partners, LLC Portfolio

Follow Arcus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arcus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arcus Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email